Ricerc@Sapienza

Although cystic fibrosis (CF) patients exhibit signs of endothelial perturbation, the functions of the cystic fibrosis
conductance regulator (CFTR) in vascular endothelial cells (EC) are poorly defined. We sought to uncover
biological activities of endothelial CFTR, relevant for vascular homeostasis and inflammation. We examined cells
from human umbilical cords (HUVEC) and pulmonary artery isolated from non-cystic fibrosis (PAEC) and CF
human lungs (CF-PAEC), under static conditions or physiological shear. CFTR activity, clearly detected in
HUVEC and PAEC, was markedly reduced in CF-PAEC. CFTR blockade increased endothelial permeability to
macromolecules and reduced trans?endothelial electrical resistance (TEER). Consistent with this, CF-PAEC displayed
lower TEER compared to PAEC. Under shear, CFTR blockade reduced VE-cadherin and p120 catenin
membrane expression and triggered the formation of paxillin- and vinculin-enriched membrane blebs that
evolved in shrinking of the cell body and disruption of cell-cell contacts. These changes were accompanied by
enhanced release of microvesicles, which displayed reduced capability to stimulate proliferation in recipient EC.
CFTR blockade also suppressed insulin-induced NO generation by EC, likely by inhibiting eNOS and AKT
phosphorylation, whereas it enhanced IL-8 release. Remarkably, phosphodiesterase inhibitors in combination
with a ?2 adrenergic receptor agonist corrected functional and morphological changes triggered by CFTR dysfunction
in EC. Our results uncover regulatory functions of CFTR in EC, suggesting a physiological role of CFTR
in the maintenance EC homeostasis and its involvement in pathogenetic aspects of CF. Moreover, our findings
open avenues for novel pharmacology to control endothelial dysfunction and its consequences in CF.